RCC1、BRCA1在152例晚期NSCLC中的表达及其临床意义  

Expression and clinical significance of RCC1 and BRCA1 in 152 patients with advanced NSCLC

作　　者：陈茹[1,2] 单利[1] 

机构地区：[1]新疆医科大学第三临床学院,新疆乌鲁木齐830054 [2]新疆维吾尔自治区人民医院

出　　处：《中国误诊学杂志》2011年第29期7070-7072,共3页Chinese Journal of Misdiagnostics

摘　　要：目的探讨ERCC1和BRCA1在晚期非小细胞肺癌(NSCLC)中的表达,分析ERCC1和BRCA1与铂类化疗近期疗效之间的关系。方法采用免疫组化法对152例晚期NSCLC中ERCC1和BRCA1的表达进行检测分析。结果 ERCC1和BRCA1的表达与各临床特征之间均无关(P>0.05),ERCCl基因蛋白表达阴性者,应用含铂方案化疗,其近期疗效明显高于表达阳性的NSCLC患者(P<0.05),BRCA1的表达与含铂化疗近期疗效无关(P>0.05)。结论结果提示ERCC1可预测NSCLC对含铂联合化疗方案的敏感性。Objective To investigate the expression of ERCC1、BRCA1 and the correlation with the clinical efficacy of platinum based chemotherapy in the advanced non small cell lung cancer.Methods We studied the expression of ERCC1、BRCA1 in 152 patients with advanced non small cell lung cancer by immunohistochemical technique.Results There were no difference between different pathological classification and clinical TNM stages,age,sexuality,smoke state neither（P0.05）.The response rate of negative ERCC1 was higher than positive ERCCl（P0.05）.The expression of BRCAl was make no difference in clinical efficacy（P0.05）.Conclusion The results suggest that the expression of ERCC1 can predict the sensitivity in advanced non-small cell lung cancer with paltinum-based chemotherapy.

关 键 词：DNA结合蛋白质类/代谢 内切核酸酶类/代谢 BRCA1蛋白质/代谢 癌 非小细胞肺/代谢 肺肿瘤/代谢 有机铂化合物/治疗应用 

分 类 号：R734.2[医药卫生—肿瘤]